In vitro metabolism of the HIV-1 protease inhibitor ABT-378: Species comparison and metabolite identification

Drug Metabolism and Disposition

Volumn 27, Issue 1, 1999, Pages 86-91

  Kumar, Gondi N ^a   Jayanti, Venkata ^a   Lee, Ronald D ^a   Whittern, David N ^a   Uchic, John ^a   Thomas, Samuel ^a   Johnson, Paulette ^a   Grabowski, Brian ^a   Sham, Hing ^a   Betebenner, David ^a   Kempf, Dale J ^a   Denissen, Jon F ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; HUMAN DEFICIENCY VIRUS 1 PROTEINASE INHIBITOR; LOPINAVIR; PROTEIN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; UREA;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MASS SPECTROMETRY; MONKEY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAT;

ANIMALIA; CANIS FAMILIARIS; HUMAN IMMUNODEFICIENCY VIRUS 1; RODENTIA;

EID: 0033043367     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzalez J, Raventos A, Rubio R, Bouza E, Pintado V, Gill Aguado A, Garcia de Lomas Delgrado JR, Borieffs JCC, Hsu A, Valdes J, Boucher CAB and Cooper DA (1995) A short-term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Eng J Med 333:1528-1533.
2. Denissen JF, Grabowski, BA, Johnson MA, Buko AM, Kempf DJ, Thomas SB and Surber BW (1997) Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs and humans. Drug Metab Dispos 25;489-501.
3. Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA. Green BE, Fina L, Park CH, Kong X-P, Wieburg NE, Salvidar A, Ruiz L, Kati WM, Sham HL, Robins T, Stewart KD, Hsu A, Plattner JJ, Leonard JM and Norbeck DW (1995) ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 92:2484-2488.
4. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A. Granneman GR, Baroldi PA, Sun E. Pizzuti D. Plattner JJ, Norbeck DW and Leonard JM (1997) Phamiacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41:654-660.
5. Kumar GN, Dykstra J, Jayanti V and Denissen JF (1997) Potent inhibition of the in vitro human liver microsomal metabolism of the HIV-1 protease inhibitor ABT-378 by ritonavir: Potential for a positive drug interaction. Proceedings of 4th Conference on Retroviruses and Opportunistic Infections, January 1997, Abstract 211.
6. Kumar GN, Rodrigues AD, Buko AM and Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277;423-431.
7. Lal RA, Hsu A, Chen P, Dennis S, El-Shourbagy T. Locke C. Lam W., Japour A. Leonard J. Granneman GR and Sun E (1997) Single dose phamiacokinetics of ABT-378 in combination with ritonavir. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 1997, Abstract I-194.
8. Lal RA, Hsu A, Granneman GR, El-Shourbagy T, Johnson M, Lam W, Manning L, Japour A and Sun E (1998) Multiple dose safety, tolerability and phamacokinetics of ABT-378 in combination with ritonavir. Proceedings of 5th Conference on Retroviruses and Opportunistic Infections, February 1998, Abstract 647.
9. Marsh K, McDonald E, Sham H. Kempf D and Norbeck D (1997) Enhancement of ABT-378 pharmacokinetics when administered in combination with ritonavir. Proceedings of 4th Conference on Retroviruses and Opportunistic Infections. January 1997, Abstract 210.
10. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo H-M, Markowitz M, Chernyavsky T, Niu TP, Lyons N, Hsu A. Granneman GR, Ho DD, Boucher CAB, Leonard JM. Norbeck DW and Kempf DJ (1996) Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 2:760-766.
11. Patick AK, Mo H, Markowitz M. Appel T, Wu B, Musick L, Kalish V, Kaldor S, Reich S, Ho D and Webber S (1996) Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 40:292-297
12. Roberts NA, Martin JA, Kinehington D, Broadhurst AV, Craig JC, Duncan IB, Galpin SA, Handa BK, Kay J, Krhn A, Lambert RW. Merrett JH, Mills JS, Parkes, KEB, Redshaw S, Ritchie AJ, Taylor DL, Thomas GJ and Machin PJ (1990) Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361.
13. Sham H, Kempf D, Molla A, Marsh K, Betebenner, D. Chen X, Kati W, Kumar G, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Chernyavsky T, Carillo A, Lloyds N, Park C, Stewart K, Plattner J and Norbeck D (1997) Design, synthesis and biological properties of ABT-378, a highly potent HIV protease inhibitor. Proceedings 4th Conference on Retroviruses and Opportunistic Infections, January 1997, Abstract 14.
14. Sharer JE, Shipley LA, VandenBranden MR. Binkley SA and Wrighton SA 11995) Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey and cynomolgus monkey. Drug Metab Dispos 23:1231-1241.
15. Shimada T, Mimura M, Inoue K, Nakamura S, Oda H, Ohmori S and Yamazaki H (1997) Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys and humans. Arch Toxicol 71:401-408.
16. Vacca JP and Condra JH (1997) Clinically effective HIV-1 protease inhibitors. Drug Discov Today 2:261-272.
17. Vacca JP, Borsey B., Schleif WA, Levin RB, McDaniel SL, Darke PL, Zugay J, Quintero JC, Blahy OM, Roth E, Sardana VV. Schlabach AJ, Graham PI, Condra JH, Gotlib L, Holloway MK. Lin J, Chen L-W, Vastag K, Ostovic D, Anderson PS, Emini EA and Huff JR (1994) L-735-524: An orally bioavailable human immunodeficiency virus type I protease inhibitor. Proc Natl Acad Sci USA 91:4096-4100.